Aurora Cannabis: International Expansion Fuels Growth Amidst Canadian Market Shifts
Aurora Cannabis Inc. (ACB) is navigating a transformative period, with robust international medical cannabis growth offsetting the challenges posed by Canadian market adjustments. The company's strategic pivot towards global medical markets is gaining momentum, reinforcing its leadership position and setting the stage for future financial recovery and expansion.
Aurora Cannabis Sees International Growth Counteract Canadian Reimbursement Cuts in Q1 FY27
Edmonton, Alberta – August 8, 2026 – Aurora Cannabis Inc. (ACB) recently unveiled its financial results for the first quarter of fiscal year 2027 (ending June 30, 2026), demonstrating a significant boost in international medical cannabis revenue. This growth has been instrumental in mitigating the effects of a substantial reduction in Canadian reimbursement rates for medical cannabis.
International medical cannabis revenue witnessed a remarkable 17% increase, reaching C$43.3 million, primarily propelled by burgeoning sales in Germany. This robust performance underscores ACB's strategic focus on establishing a formidable global medical-first platform. The international segment now constitutes a significant 64% of total net revenue, a notable rise from approximately 50% in the preceding year, showcasing the successful shift away from lower-return Canadian consumer cannabis channels.
Despite an overall net revenue decline of 9% to C$67.6 million from C$74.1 million in the prior-year period, the company's adjusted gross margin remained strong at 58%, hitting the upper end of its FY27 guidance. This resilience was achieved despite the full initial impact of a roughly 30% cut in Canadian federal medical reimbursement rates. Adjusted EBITDA for the quarter stood at C$3.4 million, reflecting diligent operating discipline in a challenging environment.
A key strategic move, the acquisition of Safari, contributed positively to adjusted EBITDA in its inaugural quarter under ACB's ownership. The Safari facility in Ontario, having secured a three-year EU-GMP certification on July 23, is poised to enhance internal supply capabilities for high-margin international markets, including Germany, Poland, Australia, and the U.K. This integration is expected to improve production efficiency, increase cultivation output, and reduce manufacturing costs, further solidifying ACB's European operational footprint.
Aurora Cannabis's liquidity position remains robust, with C$149.1 million in cash, restricted cash, and short-term investments, and notably, no outstanding loans or borrowings. This financial strength provides the company with considerable flexibility to fund strategic investments in facilities like Safari and Leuna, absorb the Canadian market reset, and explore further medical-cannabis acquisitions without incurring additional debt.
Looking ahead, management anticipates higher revenue and adjusted EBITDA in the second quarter. Street estimates suggest that while FY27 will be a transitional year due to the Canadian reimbursement adjustments, growth is expected to re-accelerate in FY28. This projected recovery is underpinned by the full contribution from Safari, increased output from the Leuna expansion, and sustained growth in key international markets, leading to positive free cash flow and improved profitability.
The company's valuation, currently trading at 0.92x FY27E Price/Sales and 4.95x FY27E EV/EBITDA, appears attractive. This suggests that the market may not yet fully appreciate the quality and long-term earnings potential of ACB's expanding international medical cannabis platform, its debt-free balance sheet, and its growing EU-GMP manufacturing capacity.
This report highlights Aurora Cannabis's ability to adapt and thrive in a dynamic market landscape. The company's strategic focus on international medical markets, combined with operational efficiencies and a strong financial foundation, positions it well for sustained growth and value creation in the coming years. The ongoing expansion in Germany, coupled with promising developments in Poland, Australia, and New Zealand, forms a strong basis for offsetting Canadian market pressures and achieving a more diversified and profitable revenue mix.
The latest quarterly update from Aurora Cannabis underscores a compelling narrative of strategic adaptation and resilient international growth in the evolving cannabis sector. Despite facing headwinds from Canadian regulatory changes, the company's concentrated efforts on global medical markets, particularly its success in Germany, demonstrate a clear path towards sustainable profitability. The attractive valuation, coupled with significant operational improvements through acquisitions like Safari and internal efficiency drives, presents an optimistic outlook. For investors and industry observers, ACB's trajectory highlights the critical importance of a diversified international strategy and robust operational control in navigating complex regulatory environments and securing long-term market leadership. The anticipated re-acceleration of growth in FY28 further reinforces the company's potential to deliver enhanced shareholder value as its global medical cannabis platform matures and expands.
